This article was published on CannabisFN
By Ryan Allway
Medical Marijuana, Inc., a premier hemp industry innovator, recently announced the appointment of Blake N. Schroeder, Esq., as Vice President of Operations at Medical Marijuana, Inc. and CEO of Kannaway LLC, a portfolio company. With extensive business experience spanning multiple industries, Mr. Schroeder will be responsible for rebranding the company as it expands into Europe and around the world.
“We are thrilled to make the announcement of Blake N. Schroeder, Esq., joining our executive leadership team,” said Stuart W. Titus, PhD and Chief Executive Officer of Medical Marijuana, Inc. “Even in turbulent economic times, Blake has consistently proven his capability of increasing revenue and growing multi-national organizations. His background with multinational marketing companies in the health and nutrition field is an extremely valuable asset. We welcome him to the MJNA team.”
“After a few visits with the executive management team at Medical Marijuana, Inc., I was crystal clear about the vision and passion behind the company, as well as the opportunity to lead in an emerging space,” said Mr. Schroeder. “The choice to join the MJNA team was simple. My goal is to consistently deliver dramatic performance results, pioneer new business strategies and improve operations. Being a natural communicator has allowed me to implement strong training and leadership structure within companies to generate positive results. I’m looking forward to implementing these proven methods and expanding Medical Marijuana, Inc.’s brand presence worldwide.”
The news comes shortly after Kannalife Sciences received a quota allotment from the Drug Enforcement Administration to import pharmaceutical grade cannabidiol into the U.S. The company plans to use the CBD in a feasibility study and preclinical trials being conducted by Catalent Pharma Solutions ahead of an Investigational New Drug application with the FDA. The team is targeting the neurodegenerative diseases hepatic encephalopathy and chronic traumatic encephalopathy with its compounds.
Kannalife Sciences hold two licenses from the NIH for patents covering cannabinoids as antioxidants and neuroprotectants that it plans to leverage to develop proprietary therapeutics targeting CTE and HE.
Medical Marijuana’s goal is to leverage its team of professionals to source, evaluate, and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. For more information, visit the company’s website at www.medicalmarijuanainc.com